Magic™ Anti-TUBB3 polyclonal antibody

Name: Magic™ Anti-TUBB3 polyclonal antibody
SKU: DPABH-27431
Rating: 5 (1 reviews)

Chicken anti-Mouse TUBB3 polyclonal antibody for WB, IHC-P, ICC/IF

Write a review

COA

SDS

Datasheet

Summary

Specifications

Antibody Isotype

IgY

Species Reactivity

Mouse

Immunogen

Synthetic peptide from a region of Mouse beta III Tubulin (Q9ERO7) conjugated to KLH.

Conjugate

Unconjugated

Applications

Application Notes

WB: 1/2000 - 1/5000; IHC-P: 5 μg/ml; ICC/IF:1/1000 - 1/2000.

Target

Alternative Names

TUBB3; tubulin, beta 3 class III; M(beta)3; M(beta)6; 3200002H15Rik; tubulin beta-3 chain; betaIII-tubulin;

Entrez Gene ID

22152

UniProt ID

Q9ERD7

Product Background

Antigen Description

Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain. TUBB3 plays a critical role in proper axon guidance and mantainance.

Pathway

Chaperonin-mediated protein folding; Diurnally regulated genes with circadian orthologs; Gap junction; Phagosome

Citations

Have you cited DPABH-27431 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Lack of Expression of TUBB3 Is a Feature of Both BCL2-Positive and BCL2-Negative Follicular Lymphoma

MODERN PATHOLOGY

Authors: Zamo, A.; Erdini, F.; Marco, C.

Abstract

Expression of excision repair cross-complementation group 1 and class III beta-tubulin in thymic carcinoma

ONCOLOGY LETTERS

Authors: Okuda, Katsuhiro; Oda, Risa; Suzuki, Ayumi; Tatematsu, Tsutomu; Haneda, Hiroshi; Moriyama, Satoru; Yano, Motoki; Nakanishi, Ryoichi

Abstract

Thymic carcinoma is a rare mediastinum malignant tumor derived from thymic epithelial cells. With the exception of complete resection, an effective therapy has not been established to date for advanced or relapsed thymic carcinoma. The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively. The expression of ERCC1 and TUBB3 proteins was examined in 40 thymic carcinoma patients who underwent either surgical resection or core-needle biopsy. The present study investigated whether the expression of ERCC1 and TUBB3 proteins was associated with the overall survival and clinicopathological factors of thymic carcinoma patients. The expression of ERCC1 and TUBB3 proteins was also evaluated in 50 patients who underwent curative resection for non-small cell lung cancer (NSCLC). The expression of ERCC1 and TUBB3 proteins was positive in 8 cases (20%) among the thymic carcinoma patients. ERCC1. was expressed in 21 cases (42%), While TUBB3 was expressed in 27 cases (54%), among the 50 NSCLC patients evaluated in the present study. Only complete resection was observed to he associated with a better prognosis than incomplete resection (P=0.0341). Other clinicopathological factors, including expression of ERCC1 and TUBB3 proteins, exhibited no effect on overall survival. The expression of ERCC1 and TUBB3 proteins in the thymic carcinoma cases was lower than that in better antitumor effects of platinum-based and taxane-based chemotherapy on thymic carcinoma patients.